Prestige partners with Cipla on Herceptin biosimilar

14 December 2018

Indian drug major Cipla (BSE: 500087) will commercialize Prestige BioPharma’s biosimilar of the Roche (ROG: SIX) cancer drug Herceptin (trastuzumab) in certain emerging markets.

Prestige is a Singapore-based biosimilars company. The HD201 copy of Herceptin is its lead program and is currently in Phase III development ahead of planned filings in Europe and the USA in 2019.

Privately-owned US pharma company Alvogen will commercialize HD201 in central and eastern Europe in a deal that was announced earlier this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK